First-hand experience with ofatumumab at ASCLEPIOS study sites in Europe

Carola Wagner¹, Laura Martin Mitjana², Joana Matos Parreira³, Massimiliano de Micco⁴

¹Novartis Pharma GmbH and on behalf of Novartis Pharma Vertriebs GmbH, Roonstr. 25, 90429 Nuremberg, Germany; ²Novartis Pharmaceuticals, Gran Via de les Corts Catalanes 764, 08013 Barcelona, Spain; ³Novartis Farma – Produtos Farmaceuticos S.A., Avenida Professor Doutor Cavaco Silva, n.º 10E, Taguspark, 2740-255 Porto Salvo, Portugal; ⁴Novartis Farma S.p.A, Largo U. Boccioni 1, 21040 Origgio, Varese, Italy

Introduction

- Ofatumumab (Kesimpta®), a fully human anti-CD20 monoclonal antibody, is approved by the European Commission for the treatment of relapsing forms of multiple sclerosis (RMS) in adults with active disease defined by clinical or imaging features.
- Ofatumumab can be self-administered at home by a once-monthly subcutaneous injection via prefilled syringe or the Sensoready® autoinjector pen¹ ²
- The phase III ASCLEPIOS I and II trials demonstrated superior efficacy and a similar safety profile of ofatumumab versus teriflunomide¹.

Objective

- As ofatumumab has been recently approved, treating physician’s first-hand experience on ofatumumab therapy from the pivotal ASCLEPIOS I and II trials is helpful for treating RMS patients with ofatumumab in clinical practice.

Methods

- As part of this survey, data was collected via an online questionnaire from ASCLEPIOS phase III study investigators. 46 investigators completed the survey (Germany, n=14; Italy, n=10; Portugal, n=10; Spain, n=12).

Results

- The benefit-risk ratio of ofatumumab was assessed as either very good (43%) or good (57%) by the investigators, none of whom gave neutral, poor, or very poor as an answer (Figure 1).

- The shorter B-cell repletion time after discontinuing ofatumumab compared to other anti-CD20 therapies³, and the consequently higher flexibility in treatment, is seen as an advantage over other anti-CD20 therapies by 91% of the investigators.
- All investigators acknowledged that treatment with the highly effective therapy ofatumumab makes sense in patients who have just experienced the onset of MS (for all patients: 28%; for highly active patients: 72%). Most investigators (93%) were in favor of self-injection of ofatumumab at home.

- Despite having only experience in the ASCLEPIOS trials with the pre-filled syringe and not the Sensoready® autoinjector pen, the results regarding improvement of patients’ quality of life, using the subcutaneous self-injection, were very positive (Figure 2).

- Investigators rate the following points, associated with the route of administration, as major to be considered when determining the treatment for patients: respecting patient’s relevant wishes (83%), the expected compliance of the patient (83%), possible side effects associated with the route of administration (63%) and the practice’s/hospital’s capacities (54%).

- 44% of the investigators considered Serum Neurofilament light chain (NfL) and 81% total B-cell and B-cell subtype counts as (very) important to be monitored in clinical practice (Figure 3).

Conclusions:

- After gaining experience with ofatumumab within clinical trials, European neurologists consider ofatumumab a very efficient and safe treatment option.
- They rate the self-administered subcutaneous injection once a month as offering high convenience for patients and as facilitating processes at high-occupancy clinics and office-based practices.
- All investigators consider ofatumumab as a therapy option for newly diagnosed patients.
- Limitation: A detailed inquiry of the risk and safety assessment for ofatumumab was not part of this survey

References

2. Bar-Or A et al. Poster presentation at ACTRIMS 2020; West Palm Beach, Florida, USA
3. Savelieva M et al. Poster presentation at ECTRIMS 2017; Paris, France


This study was sponsored by Novartis Pharma GmbH, Nuremberg, Germany.